Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TELA Bio, Inc. is a commercial-stage medical technology company operating in the surgical reconstruction and soft-tissue repair industry. The company focuses on developing, manufacturing, and commercializing biologically derived surgical meshes designed to reinforce soft tissue during hernia repair and abdominal wall reconstruction. TELA Bio’s core value proposition centers on providing alternatives to permanent synthetic mesh by leveraging bioengineered materials intended to support long-term tissue remodeling.
The company’s primary revenue is generated from sales of its flagship products, including OviTex and OviTex PRS, which are used primarily by surgeons in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. TELA Bio differentiates itself through its proprietary reinforced biologic technology, which combines layers of biologic tissue with minimal permanent polymer reinforcement. Founded in 2012, the company progressed from early clinical development to U.S. commercialization and completed its initial public offering in 2020, marking its transition to a publicly traded entity.
Business Operations
TELA Bio operates through a single-reportable operating segment focused on the commercialization of surgical mesh products. Revenue is primarily generated through direct sales in the United States, where the company maintains a specialized sales force targeting hospitals and surgical centers. International revenue is limited but includes distributor-based sales in select markets outside the U.S.
The company controls proprietary manufacturing processes for its reinforced biologic platforms and maintains quality and regulatory oversight aligned with FDA requirements. Key products include OviTex, OviTex PRS, and OviTex Resorbable, each addressing different clinical needs across soft-tissue repair applications. TELA Bio does not currently rely on large-scale joint ventures, but it does maintain third-party manufacturing and processing relationships essential to its supply chain.
Strategic Position & Investments
TELA Bio’s strategic direction emphasizes expanding surgeon adoption, increasing clinical evidence, and broadening indications for its reinforced biologic platform. Growth initiatives include expanding its commercial footprint, investing in post-market clinical studies, and launching next-generation products such as OviTex Resorbable, which eliminates permanent polymer components.
The company has pursued growth primarily through internal research and development rather than large acquisitions. Strategic investments are focused on product innovation, surgeon education, and operational scale rather than portfolio diversification. Emerging areas of focus include complex hernia repair and applications within plastic and reconstructive surgery, where demand for biologic reinforcement continues to grow.
Geographic Footprint
TELA Bio is headquartered in Malvern, Pennsylvania, and its operations are primarily concentrated in the United States, which represents the vast majority of its revenue and commercial activity. The company maintains sales and marketing operations across major U.S. hospital systems and regional surgical centers.
Internationally, TELA Bio has a limited but growing presence through select distribution partners in Europe, the Middle East, and other international markets. While global operations are not yet a primary revenue driver, international expansion remains a secondary strategic objective as regulatory approvals and distributor relationships develop.
Leadership & Governance
TELA Bio was co-founded by experienced medical device executives with backgrounds in biologic materials and surgical technologies. The company’s leadership emphasizes evidence-based product development, disciplined commercialization, and long-term value creation through clinical differentiation rather than price competition.
Key members of the leadership team include:
- Adam L. Davis – President and Chief Executive Officer
- Michael V. Elia – Chief Financial Officer
- Jeffrey W. Goh – Chief Commercial Officer
- Robert W. Shaw – Chief Operating Officer
- Frank J. Menzies – Chief Medical Officer
The company is governed by a board of directors with experience across medical devices, healthcare investing, and public company governance, supporting oversight, risk management, and strategic execution.